Topics

FDA Grants Priority Review to Frontline Nivolumab/Ipilimumab in Advanced NSCLC

13:56 EST 15 Jan 2020 | OncLive

The FDA has granted a priority review designation to a supplemental biologics license application for the combination of nivolumab and ipilimumab for the first-line treatment of patients with metastatic or recurrent non–small cell lung cancer that does not have EGFR or ALK genomic tumor aberrations.

Original Article: FDA Grants Priority Review to Frontline Nivolumab/Ipilimumab in Advanced NSCLC

NEXT ARTICLE

More From BioPortfolio on "FDA Grants Priority Review to Frontline Nivolumab/Ipilimumab in Advanced NSCLC"

Quick Search

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Biotherapeutics
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...